ACADIA Pharmaceuticals Stock Buy or Sell? ACAD Stocks Forecast

Market Capitalization: 4 122 560 000 $
EBITDA: -149 982 000 $
Price to Earnings: None
Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: 0.62
Trailing PE: -
Forward PE: 34.84
Shares Outstanding: 164180000






Trading Penny Stocks for Profit: Expert Insights and Practical Advice

February 22, 2024 Trading Penny Stocks for Profit: Expert Insights and Practical Advice

For aspiring traders and seasoned investors alike, the enticing appeal of penny stocks can be likened to voyaging across the vast oceans, discovering…
Getting A Kredittkort Norge Approval Isn’t Difficult

February 8, 2024 Getting A Kredittkort Norge Approval Isn’t Difficult

If you meet the conditions, you can open an account for checking in Norway. However, it will be much easier and more convenient…
How to Understand Social Security: 6 Legal & Financial Tips

January 25, 2024 How to Understand Social Security: 6 Legal & Financial Tips

Understanding social security can seem overwhelming, but it’s an important part of financial planning, particularly for retirement. The following 6 legal and financial…
Finding Energy Plans with Billig Strøm Rates

January 10, 2024 Finding Energy Plans with Billig Strøm Rates

It can be overwhelming to decide on the best plan when in a state where electricity is deregulated. The number of providers is…

ACADIA Pharmaceuticals Stock Buy or Sell? ACAD Stocks Analytic Forecasts

Updated on February 24, 2024 (09:16)

ACADIA Pharmaceuticals Inc. (ACAD prediction charts) Sector: Healthcare

We present you the most up-to-date and complete review of analytical trend forecasts and views on the ACAD stock market. Experts share their opinions on what to expect from the ACADIA Pharmaceuticals Inc. stock market. How likely is the stock price to move in a bullish or bearish trend. Which should help you to make the right decision whether to Buy or Sell ACADIA Pharmaceuticals stocks.

ACADIA Pharmaceuticals Inc. Stock Market Experts’ Analysis and Forecasting – Sell or Buy ACAD Shares?

The most recent analytical view which can help you to answer the worrying question: Should I Buy Stocks Now or Wait? came out under the authorship of ONeil Trader and is titled

“Acadia Pharmaceuticals: Legal Overhang On Nuplazid Removed”

is published on December 13 (2023) and has 0 likes. The review predicts Bullish market trend.

It summarize the following theses:

  • Shares of Acadia Pharmaceuticals surged after the Court granted a summary judgment in the Nuplazid patent case in its favor.
  • The positive outcome removes an important legal overhang on ACAD stock and further share price advancements can be driven by Daybue’s commercial success.
  • Daybue continued to exceed expectations with a Q3 net sales beat and a strong Q4 outlook.
  • Nuplazid’s phase 3 results in negative symptoms in schizophrenia patients represent the key clinical catalyst in early 2024.

The author starts his analytic review with the following:

Why Acadia stock surged today Shares of Acadia Pharmaceuticals (NASDAQ:ACAD) surged today after the U.S. District Court for the District of Delaware granted a summary judgment in the Nuplazid patent case against MSN Pharmaceuticals. This case was the reason Acadia’s share price was suppressed lately despite the strong launch of Daybue and the overall pipeline progress with Nuplazid’s successor ACP-204 advancing into a phase 2/3 trial in Alzheimer’s disease psychosis and ACP-101 advancing into a phase 3 trial in Prader-Willi syndrome.

The opinion of the author can be considered quite authoritative.
The number of 7730 followers confirms this.
ONeil Trader is the contributor of experts community
since 2012 and has 779 works published.


One more noteworthy article is written by Stephen Ayers under the title

“Acadia’s Daybue: A Small Patient Pool Making Big Waves”

on December 10 (2023) and has 0 likes. The expert reflects Bullish trend of the market.

Нis theses make you think about whether to add ACAD stocks to your investment portfolio or not, and helps to work out your own ACADIA Pharmaceuticals stock selling strategies:

  • Acadia’s Daybue, treating Rett syndrome, shows strong market entry with sales of $90.1 million in the first six months, indicating significant market potential.
  • Acadia’s financials are robust with rising net product sales and a strong current ratio, but increasing operating expenses and net losses.
  • Market confidence in Acadia is moderate, with high institutional ownership and insider buying, but mixed stock momentum.
  • Recommend “Buy” for Acadia due to Daybue’s market potential, despite the need for careful financial management and market monitoring.

Stephen Ayers starts analysis with such words:

At a Glance Reflecting on my previous assessment of Acadia Pharmaceuticals (NASDAQ:ACAD), where I changed my stance from “Hold” to “Buy,” the company’s progression, particularly with Daybue for Rett syndrome, remains intriguing. Daybue’s impressive Q3 sales of $66.9M, building upon the $23.2M in Q2, highlight its market promise in a specialized area. Despite a limited patient base, growing confidence is evident through analyst upgrades and optimistic sales forecasts. Acadia’s recent increased spending on milestones and operational costs for Daybue’s launch, along with its expanded partnership with Neuren Pharmaceuticals, showcases a deep commitment to the neurological sector. Financially, Acadia stands strong with a substantial cash reserve, yet the imperative for judicious capital management to balance investments and operational expenses is more crucial than ever.

The opinion of the author can be considered quite authoritative.
The number of 5613 followers confirms this.
Stephen Ayers is the contributor of experts community since 2017. Has already published at least 544 articles.


Another analysis presented by ONeil Trader came out on September 26 (2023). Obviously, coupled with the newer reviews, this forecasting could be useful to find out the best trading strategy for ACAD stocks. It sounds like

“Acadia Pharmaceuticals: Difficult Market Masks Progress”

Article has got 0 likes at the moment and forecasting Bullish trend of the market.

Summarizing the information presented in the review concerning the ACADIA Pharmaceuticals Inc., the expert says the following:

  • Acadia Pharmaceuticals’ gains recently disappeared despite the strong launch of Daybue.
  • Poor market conditions are to blame, especially the poor biotech investor sentiment.
  • Daybue’s sales in Q2 exceeded expectations, with Q3 sales expected to be in the $45-55 million range.
  • Nuplazid is doing well despite significant cost cuts, but further indication expansion is needed for the product to start growing faster again.

And here, what comes first:

Shares of Acadia Pharmaceuticals (NASDAQ:ACAD) are barely higher since my previous article despite a significant improvement in fundamentals. Nuplazid is doing largely as expected but the launch of Daybue has far exceeded expectations. I previously argued that peak annual sales of Daybue could be $350 million at the low end of the range and up to $700 million at the high end of the range, and while I admit it is too early to say this with confidence, it is entirely possible that the low end of the range is very conservative, especially now that the company has secured commercial rights outside of North America.

The opinion of the author can be considered quite authoritative.
The number of 7632 followers confirms this.
ONeil Trader is the contributor of experts community since 2012. Has already 764 analytic reviews published.


The Share Price of ACADIA Pharmaceuticals Inc. (ACAD) for now

What analysts predict: $34.25
52-week high/low: $33.99 / $17.71

50/200 Day Moving Average: $27.43 / $25.45

The average stock price over the previous 50/200 days. For ACADIA Pharmaceuticals stocks, the 50-day moving average is the resistance level for now. For ACAD stocks, the 200-day moving average is the resistance level today.

See the Detailed Predictions for ACAD stock with charts and tables

Related Analysis

View all analytics

Buy or Sell ADGI shares?
January 1, 1970

Thermo Fisher’s Bright Future Makes It A Great Buy On Weakness

Buy or Sell TMO shares? Thermo Fisher’s Bright Future Makes It A Great Buy On Weakness
February 6, 2024
Drug manufacturers are facing a massive patent cliff, with over $200 billion in annual revenue at risk through 2030, meaning innovation is critical to prop up sales, and today's company focuses on that.

Revisiting Zynerba Pharmaceuticals

Buy or Sell ZYNE shares? Revisiting Zynerba Pharmaceuticals
November 11, 2021
Today, we revisit a small developmental firm called Zynerba Pharmaceuticals.

Danaher: Better Positioned For The Future

Buy or Sell DHR shares? Danaher: Better Positioned For The Future
February 3, 2024
Danaher's annual results show a decrease in sales and EBIT due to the boost in sales of the COVID-19 pandemic.